Jinjie Liu

Jinjie Liu

Auto-generated profile, based on publicly available information

Jinjie Liu

Central Hospital of Dalian University of Technology Department of Neurology Dalian, 116033

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2023 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
PDF file
LLLiping Liu
Liping Liu
ZPZi-Xiao Li PhD
Zi-Xiao Li PhD
HZHongyu Zhou
Hongyu Zhou
WDWanying Duan
Wanying Duan
XHXiaochuan Huo
Xiaochuan Huo
YWYongjun Wang
Yongjun Wang
Background: China is one of the countries with the highest burden of stroke. Implementing multidimensional management guidelines will help clinicians practise evidence-based care, improve patient outcomes and alleviate societal burdens. This update of the 2019 edition will provide the latest comprehensive recommendations for the diagnosis and treatment of ischaemic cerebrovascular diseases. Methods: We conducted a comprehensive search on MEDLINE (via PubMed) up to 31 August 2023. The writing team established the recommendations through multiple rounds of online and offline discussions. Each recommendation was graded using the evidence grading algorithm developed by the Chinese Stroke Association (CSA). The draft was reviewed and finalised by the CSA Stroke Guidelines Writing Committee. Results: This update included revisions of 15 existing recommendations and 136 new recommendations in the following areas of stroke care: emergency assessment and diagnosis of ischaemic cerebrovascular disease, acute-phase reperfusion therapy, evaluation of underlying mechanisms, antithrombotic therapy, prevention and treatment of complications, and risk factor management. Conclusions: This guideline updated the recommendations for the clinical management of ischaemic cerebrovascular disease from 2019.

23 September 2024 in Annals of Medicine
Verified
Journal Article
Open access
SLSibo Liu
Sibo Liu
HWHong Yu Wu
Hong Yu Wu
MDMei Li Duan
Mei Li Duan
RYRong Li Yang
Rong Li Yang
CJChen Hua Ji
Chen Hua Ji
HZHongtao Zhao
Hongtao Zhao
Delirium in critical ill patients is a complex and common neurological syndrome in the intensive care unit (ICU) that is caused by a range of structural or functional abnormalities. ICU Delirium is associated with reduced compliance, prolonged hospital stays, greater use or delayed withdrawal of sedatives, higher rates and durations of mechanical ventilation, and higher rates of mortality. The aetiology and pathogenesis of ICU delirium are unclear, and the lack of better prediction, prevention, and treatment measures leads to a non-standardized control of delirium. By searching the relevant literature, we aim in this narrative review to describe progress in the pathogenesis, predictive biomarkers, diagnosis, and treatment of ICU delirium.

25 April 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
SLSibo Liu
Sibo Liu
YLYanzhao Li
Yanzhao Li
XLXiaoyan Lan
Xiaoyan Lan
LWLong Wang
Long Wang
HLHang Li
Hang Li
JLJinjie Liu
Jinjie Liu
Background: The objective was to provide standardized, comprehensive, and updated estimates of the global, regional, and national burdens of and risk factors for ischaemic stroke (IS) in adults aged 20 years and older.Methods: This was a population-based study (Global Burden of Disease, Injuries and Risk Factors Study 2021). Adults aged 20 years and older from 204 countries and territories and 811 subnational locations from 1990 to 2021 were included. The primary outcomes were IS-related age-standardized prevalence, mortality, disability-adjusted life years (DALYs), average annual percentage change (AAPC), and risk factors associated with DALYs.Results: From 1990 to 2021, the global age-standardized prevalence of IS decreased from 1,309 (95% UI 1,151 to 1,481) to 1,266 (95% UI 1,120 to 1,423) cases per 100,000 population, with an average annual decrease of −0.12%. However, the prevalence increased notably in the middle sociodemographic index (SDI) regions and East Asia but remained stable in Southeast Asia. The total number of IS cases still increased significantly from 33.2 million to 68.4 million. During the same period, the overall age-standardized mortality for IS decreased from 116 to 70 cases per 100,000 population, with an average annual change of −1.60%. Similarly, the overall age-standardized DALYs for IS decreased by 35%, with an average annual change of −1.36%. The decrease in both the age-standardized mortality and DALY rates was correlated with the SDI, with the most rapid decrease occurring in high-SDI regions. Conversely, in subregions of southern sub-Saharan Africa, an increase was observed. Males consistently faced a greater burden of IS across all subgroups. High systolic blood pressure and high low-density lipoprotein cholesterol (LDL-C) levels consistently represented the most significant risk factors contributing to DALYs from 1990 to 2021.Conclusion: Globally, the total IS caseload has increased. Targeted strategies, such as metabolic risk control in high-SDI regions, low-cost interventions in middle-/low-SDI regions, and improved neuroimaging infrastructure in sub-Saharan Africa, are needed. Future research should focus on subtype-specific burdens, the legacy effects of COVID-19, and intervention cost effectiveness to guide policymakers in developing efficient strategies to combat the global burden of ischaemic stroke.

11 March 2025 in Annals of Neurology
Verified
Journal Article
Closed access
XNXiming Nie
Ximing Nie
JLJinjie Liu
Jinjie Liu
BYBernard Yan
Bernard Yan
FNFelix C. Ng
Felix C. Ng
SLSibo Liu
Sibo Liu
FGfor the ANGEL‐ASPECT Study Group
for the ANGEL‐ASPECT Study Group

29 January 2026 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
SLSibo Liu
Sibo Liu
GWGuozhi Wu
Guozhi Wu
XMXiao Ma
Xiao Ma
KXKai Xu
Kai Xu
XLXiaoyan Lan
Xiaoyan Lan
JLJinjie Liu
Jinjie Liu
Background: Alzheimer’s disease and other dementias (ADOD) pose a significant global health challenge, with projected annual increases. The growing elderly population exacerbates burdens, underscoring the need for interventions. Methods: Using data from the Global Burden of Disease Study 2021, we analysed global ADOD trends from 1990 to 2021 among adults aged 65+ and projected to 2050. Average annual percentage change (AAPC) in the age-standardised prevalence, mortality and disability-adjusted life years (DALYs) rates of ADOD were calculated to quantify the temporal trends. Results: Globally, the number of adults aged 65 years or older living with ADOD increased from 18.1 (95% uncertainty interval [UI] 14.4–22.5) million in 1990 to 49.1 (38.7–61.3) million in 2021 (AAPC 0.09%). While mortality rates remained relatively stable (AAPC 0%), DALYs increased by 176% (AAPC 0.02%). Females consistently exhibited a higher age-standardised prevalence (7,603 [95% UI 6,023–9,469] cases per 100,000 population) vs. 5,744 [4,486–7,205]) and mortality (304 [78 to 782] vs. 225 [54–626]) rate compared to males, with notable regional variations. From 1990 to 2021, the age-standardised prevalence of ADOD increased only in East Asia and High-income Asia Pacific (AAPC 0.79% and 0.16%). High fasting plasma glucose, high body-mass index, and smoking were identified as primary risk factors. Projections indicate a 50.1% increase in age-standardised prevalence by 2050, with an estimated 191 (52–330) million cases, and a predicted death toll of 6.8 (2.4–11.3) million. Conclusion: The global number of people living with dementia nearly tripled from 1990 to 2021, mainly due to increases in population ageing and growth. The findings emphasize the need for comprehensive strategies to address ADOD, including prevention, early diagnosis, and effective management, with a focus on gender and regional disparities.

1 July 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
BLBo Si Liu
Bo Si Liu
RZRui Zhao
Rui Zhao
RYRongLi Yang
RongLi Yang
HZHongLing Zhao
HongLing Zhao
CJChenHua Ji
ChenHua Ji
JLJinJie Liu
JinJie Liu
The efficacy and safety of dexmedetomidine and olanzapine for delirium control in critically ill elderly patients without ventilation or surgery are not known. The efficacy and safety of dexmedetomidine and olanzapine for controlling delirium were evaluated in a retrospective cohort of critically illness by assessing the sedation level, drug dose/duration, combination rate with other sedatives, adverse effects, intubation rate and prognosis. The maximum (1.61 ± 1.56 vs. 2.70 ± 1.01, p < 0.001), average (-0.57 ± 0.88 vs. 0.88 ± 0.73, p < 0.001), and minimum (-1.67 ± 1.04 vs. -1.37 ± 1.01, p = 0.014) RASS scores of 263 patients were lower after treating with dexmedetomidine than treating with olanzapine. Drug use duration (4.83 ± 2.67 days vs. 5.87 ± 3.14 days, p = 0.005) and sedative combination rates (13.56% vs. 40.00%, p = 0.003) were lower when treating with dexmedetomidine than that with olanzapine. A comparison of adverse effects between dexmedetomidine and olanzapine revealed respiratory depression (16.95% vs. 2.84%, p < 0.001), hypoxia (13.56% vs. 2.76%, p < 0.001) and hypotension (11.02% vs. 3.45%, p = 0.007). Intubation rates (22.88% vs. 12.41%, p = 0.023) and the length of hospital stay (9.30 ± 4.90 days vs. 8.83 ± 3.34 days, p < 0.001) were higher in patients treated with dexmedetomidine than that with olanzapine. Mortality rates, cognitive prognosis, and delirium recurrence rates were similar between groups. Age, severe cardiopulmonary disease, APACHE II scores, dexmedetomidine dose, minimum RASS score and sedative combination were significantly (p < 0.05) associated with the adverse effects of dexmedetomidine. Respiratory depression, hypoxia and hypotension in the olanzapine group all occurred during combination with benzodiazepines. Dexmedetomidine achieved more satisfactory sedative effects on delirium control, but olanzapine was safer.